World Health Organization Raises Warning Over Acute Lack of Obesity Jabs

Less than 10% of people eligible to benefit from GLP-1 drugs like Wegovy are able to get them, states the WHO as it publishes its first guidance on the medications.

Considering more than one billion people worldwide currently living with obesity, it is urging broader and more equitable availability to this class of drugs.

Per forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.

"Our latest guidance recognises that obesity is a chronic disease that can be addressed with thorough and continuous support," stated its chief Tedros Adhanom Ghebreyesus.

Significant expense, constrained manufacturing, and distribution challenges are significant hurdles to broad availability to the jabs that can assist patients in reducing substantial weight, says the body.

GLP-1 Therapy Scarcity

Even in the present best projected case, the supply of these medications might only reach around 100 million people – less than 10% of those who need them, as stated by the health organization.

The advice calls on nations and manufacturers to widen availability, via measures such as voluntary licensing.

A patent on semaglutide – the primary component of the drug Wegovy – is scheduled to end in a number of countries in 2026.

How Obesity Jabs Work

These medications mimick a biological compound to reduce digestion speed, curb appetite and boost the sense of being full so users reduce food intake.

Individuals typically begin shedding pounds within a few weeks of beginning the once-weekly jabs.

Studies points to people may regain a significant portion within a year of stopping the treatment, because their normal hunger resume.

Being carrying excess weight increases your likelihood for contracting medical conditions, including diabetes, heart disease, stroke, and certain malignancies.

Obesity affects people in all nations and was responsible for millions of deaths worldwide in 2024, as per the WHO.